Recently, Valiant Pharmaceutical’s first active pharmaceutical ingredient (API), olmesartan medoxomil, successfully passed the rigorous review of the European Directorate for the Quality of Medicines and HealthCare (EDQM) and obtained the Certificate of Suitability to the European Pharmacopoeia (CEP), supported by its advanced and independently developed research and production process.
The certification signifies that the company’s API production and quality control systems have reached internationally recognized authoritative standards, granting it access to the high-end and mainstream pharmaceutical markets of the European Union and the global market.
CEP certification is an important qualification in the global API sector and is known for its stringent review process. This achievement highlights the company’s strong capabilities in research, development and quality management, laying a solid foundation for further expansion into international markets. In the future, the company will continue to follow international standards, promote the globalization of more API products, and enhance its global competitiveness.
